Paradigm4’s REVEAL Integrative Analytics platform enables Alnylam Pharmaceuticals to discover novel, genetically-validated drug targets from population scale biobank genotype-phenotype datasets and underlies the extraordinary pace and productivity of Alnylam’s RNAi therapeutics pipeline.
Addressing the vital economic challenge of uncovering new critical quality attributes (CQAs), Paradigm4’s REVEALTM Analytical Development app enables data analysts…
Paradigm4 has launched its REVEAL™: Multi-Omics app, allowing researchers to undertake advanced, cross-study analyses and enable quick searches for genes and proteins across all integrated public reference and proprietary datasets.